FDA批准Urcosimod(0.05%)治疗稀有的、严重的神经病态角膜疼痛。 FDA approves Urcosimod (0.05%) for rare, severe neuropathic corneal pain.

美国食品和药品管理局批准以同情方式使用Urcosimod(0.05%)治疗神经病性角膜疼痛,这是一种罕见和严重的眼病,由于角膜神经损伤导致慢性疼痛。 The U.S. Food and Drug Administration has approved compassionate use of Urcosimod (0.05%) for treating neuropathic corneal pain, a rare and severe eye condition causing chronic pain due to nerve damage in the cornea. 批准使没有其他治疗选择的病人能够在严格监督下获得药物。 The approval allows patients with no other treatment options to access the drug under strict oversight. OKYO Pharma Ltd.宣布了这一决定,标志着在解决这种衰弱状况未得到满足的医疗需求方面迈出了重要一步。 OKYO Pharma Ltd. announced the decision, marking a significant step in addressing unmet medical needs for this debilitating condition.